checkAd
    Startseite > Aktien > Autolus Therapeutics > Nachrichten
    Autolus Therapeutics Aktie
    4,2900
     
    USD
    +2,39 %
    +0,1000 USD
    Letzter Kurs 05.06.24 Nasdaq
    4,2900
     
    USD
    500 STK
    Geldkurs 05.06.24
    4,3000
     
    USD
    300 STK
    Briefkurs 05.06.24
    ISIN: US05280R1005 · WKN: A2JNZJ · SYM: AUTL · Großbritannien

    Neueste Nachrichten

    Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
    31.05.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
    17.05.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    14.05.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
    13.05.24 · globenewswire · Autolus Therapeutics
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 26.04.2024
    26.04.24 · wO Chartvergleich · Boyd Gaming
    Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
    24.04.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    23.04.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
    02.04.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics Announces Changes to its Board of Directors
    01.04.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
    14.03.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
    12.03.24 · globenewswire · Autolus Therapeutics
    Autolus Therapeutics announces publication in Blood Cancer Journal
    11.03.24 · globenewswire · Autolus Therapeutics